Ares Financial Consulting
VRTX icon

Ares Financial Consulting’s Vertex Pharmaceuticals VRTX Stock Holding History

Ares Financial Consulting’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$128K Hold
245
– – 0.09% 120
2026
Q2 		$122K Buy
245
+5
+2% +$2.22K 0.09% 127
2026
Q1 		$107K Buy
240
+167
+229% +$77.9K 0.08% 123
2025
Q4 		$33.1K Buy
+73
New +$31.5K 0.03% 205

Other funds holding VRTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Ares Financial Consulting's VRTX Position: Q3 2026 in Review

Ares Financial Consulting held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2026 at 245 shares worth $128K. The position accounts for 0.09% of the portfolio, ranked #120.

Ares Financial Consulting first reported a position in VRTX in Q4 2025 and has held it in 4 quarters since. 992 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Ares Financial Consulting held 245 shares of Vertex Pharmaceuticals worth $128K as of Q3 2026.
  • Ares Financial Consulting left its Vertex Pharmaceuticals share count unchanged in Q3 2026.
  • Vertex Pharmaceuticals made up 0.09% of Ares Financial Consulting's portfolio in Q3 2026, its #120 holding.
  • Ares Financial Consulting first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • 992 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.